Form 4: Aligos Therapeutics Director Acquires Stock Options

Aligos Therapeutics Director Bridget A. Martell acquired stock options for 5,860 shares of common stock.

Summary

• Bridget A. Martell, a Director at Aligos Therapeutics, Inc., acquired stock options on June 25, 2026.
• The options grant the right to purchase 5,860 shares of common stock at an exercise price of $5.50 per share.
• These options are set to expire on June 25, 2036.
• The shares subject to the option will vest and become exercisable on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027, provided continuous service to the Issuer through such vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation and incentive mechanism for a director rather than a significant strategic or financial development.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule aligns with continued service, encouraging long-term commitment.

Future Outlook

The vesting schedule indicates a forward-looking commitment from the director, contingent on continued service and company performance milestones.

Industry Context

StockSavvy.ai notes that director acquisitions of stock options are common in the biotechnology sector as a means to incentivize and retain key leadership, aligning their interests with shareholders.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as a sign of commitment, but it does not immediately impact share price or ownership structure.

Next Steps

• Director Martell will continue to serve Aligos Therapeutics, Inc.
• The stock options will vest according to the schedule outlined.

Key Dates

Keywords

stock options, insider trading, Aligos Therapeutics, director, common stock, vesting schedule, SEC Form 4